Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics was a biopharmaceutical company focused on therapies for allergic and immunologic diseases before becoming a wholly owned subsidiary of BioCryst Pharmaceuticals in 2026. Company news centered on navenibart, also known as STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein in clinical development for hereditary angioedema, and STAR-0310, an investigational monoclonal antibody OX40 antagonist for atopic dermatitis.
Recurring updates covered clinical trial results and scientific meeting presentations, licensing and material agreements, operating and financial results, capital-structure disclosures, governance matters, and shareholder votes tied to Astria's corporate transition.
Astria Therapeutics, Inc. (NASDAQ:ATXS) will present a poster titled "Burdens of Disease and Treatment in Hereditary Angioedema: Interview Insights from HAE Patients" at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit. This presentation highlights insights from patients suffering from hereditary angioedema (HAE) and will be accessible to event registrants from October 18, 2021, to November 18, 2021. Astria is developing STAR-0215, a monoclonal antibody aimed at treating HAE.
Astria Therapeutics (NASDAQ:ATXS) announced that CEO Jill C. Milne, Ph.D., will present an overview of the company and its lead program, STAR-0215, which targets hereditary angioedema (HAE), at two upcoming virtual investor conferences. The presentations will take place at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, and the Oppenheimer Fall Healthcare, Life Sciences, and MedTech Summit on September 22, 2021. Webcasts can be accessed through Astria's investor section on their website and will be available for 30 days post-event.